Lilly's obesity pill heads for diabetes filing after heart risk trial
After ACHIEVE-4 showed Foundayo cut major cardiovascular events by 16% versus insulin, Lilly plans to file for a type 2 diabetes indication by end of Q2 2026. A diabetes approval would expand prescribing beyond obesity specialists and open broader insurance coverage for the $149/month oral GLP-1.
What This Means for You
After ACHIEVE-4 showed Foundayo cut major cardiovascular events by 16% versus insulin, Lilly plans to file for a type 2 diabetes indication by end of Q2 2026. A diabetes approval would expand prescribing beyond obesity specialists and open broader insurance coverage for the $149/month oral GLP-1.
Lilly is filing Foundayo for type 2 diabetes before the end of Q2 2026. If approved, this changes who can prescribe it, who pays for it, and how many people can access it.
Right now, Foundayo is approved only for chronic weight management. That means your prescriber needs to document a BMI of 30+ (or 27+ with a comorbidity) and frame the prescription around obesity. Many insurance plans are stingy with weight-loss drug coverage: prior authorizations, step therapy requirements, or outright exclusions are common. A type 2 diabetes indication would bypass most of those barriers. Diabetes medications live on a completely different tier of insurance formularies. Your endocrinologist or primary care doctor could prescribe Foundayo the same way they prescribe metformin or insulin, with far less friction from your insurer.
The clinical case for the filing is strong. ACHIEVE-4 showed Foundayo cut MACE risk by 16% compared to insulin glargine (HR 0.84), delivered better HbA1c reductions at 52 and 104 weeks, and produced weight loss that insulin can’t match. For the roughly 37 million Americans with type 2 diabetes, many of whom also have obesity, a single daily pill at $149/month that improves blood sugar, reduces weight, and has at least as good a cardiovascular safety profile as insulin is a compelling option. The all-cause mortality signal (57% lower, HR 0.43) adds to the case, even though it needs confirmation in dedicated trials.
The practical impact for patients: if you have type 2 diabetes and are currently on insulin or sulfonylureas, a Foundayo approval for T2D means your doctor could switch you to an oral GLP-1 that addresses both your blood sugar and your weight. That’s fewer injections (potentially zero if you drop insulin entirely), lower cardiovascular risk, and a $149/month price tag that beats many insulin regimens. Telehealth providers like Ro and PlushCare already prescribe Foundayo for weight management and would likely add diabetes prescribing once the indication is approved. Dedicated diabetes management programs from providers like Calibrate could integrate Foundayo as a first-line therapy.
The filing timeline suggests an FDA decision by late 2026 or early 2027. In the meantime, if you have both type 2 diabetes and obesity, your doctor can prescribe Foundayo off-label for the weight management indication while treating your diabetes with existing medications. Talk to your provider about whether adding Foundayo to your current regimen makes sense.
Source: Endpoints News
Frequently asked questions
Can my doctor prescribe Foundayo for diabetes right now, before the T2D approval?
Foundayo is currently approved only for weight management, but doctors can prescribe any FDA-approved medication off-label based on clinical judgment. If you have type 2 diabetes and obesity, your doctor could prescribe Foundayo under the weight management indication. However, your insurance may not cover it for diabetes until the T2D indication is formally approved. The $149/month self-pay price makes out-of-pocket treatment feasible if insurance denies coverage.
How would a diabetes indication change Foundayo’s price?
Lilly hasn’t signaled any price change tied to a T2D indication. The $149/month self-pay and $25/month insured copay would likely remain the same. What changes is coverage: diabetes formulary placement typically means lower copays, fewer prior authorizations, and coverage through Medicare Part D (which currently limits weight-loss drug coverage). You’d be paying the same or less for the same drug, just through a different insurance pathway.
Would Foundayo replace insulin for type 2 diabetes patients?
For some patients, possibly. ACHIEVE-4 showed Foundayo delivered better blood sugar control than insulin glargine over two years, with added weight loss and at least comparable cardiovascular safety. But not everyone with T2D can stop insulin. Patients with very high HbA1c, long-standing diabetes, or significant beta cell dysfunction may still need insulin alongside or instead of Foundayo. The decision to switch or add Foundayo to an insulin regimen should be made with your endocrinologist based on your specific situation.
Keep reading
Frequently Asked Questions
Can my doctor prescribe Foundayo for diabetes right now, before the T2D approval?
How would a diabetes indication change Foundayo's price?
Would Foundayo replace insulin for type 2 diabetes patients?
Original source
Read the full article at Endpoints News